Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Lunning

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Clinical Advances in Hematology & Oncology : H&O|January 6, 2023
Autologous and allogeneic CAR T-cell therapies: spotlighting the "brain-to-vein" timeMatthew Lunning
Oncology (Williston Park, N.Y.)|June 20, 2022
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"Meghana Kesireddy, Matthew Lunning
Journal of Oncology Practice|June 12, 2019
Hepatosplenic γ-δ T-Cell Lymphoma: Who Is on Your Speed Dial?Mridula Krishnan, Matthew Lunning
Cancer Journal (Sudbury, Mass.)|May 21, 2026
Hodgkin Lymphoma: Introduction and HistoryJames Armitage, Matthew Lunning
The New England Journal of Medicine|September 17, 2025
Tumor Lysis SyndromeR Gregory Bociek, Matthew Lunning
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 16, 2007
The curability of follicular lymphomaMatthew Lunning, James O Armitage
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Addressing the Challenges of Aggressive LymphomasKatherine L Byar, Matthew Lunning
Leukemia & Lymphoma|June 17, 2024
Experience of using venetoclax in relapsed T- cell lymphomaJasmine Zain, Matthew Lunning, Steven Rosen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the ArtJeremy S Abramson, Matthew Lunning, M Lia Palomba
Current Hematologic Malignancy Reports|May 4, 2019
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLLAdam S Kittai, Matthew Lunning, Alexey V Danilov
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Clinical Advances in Hematology & Oncology : H&O|January 6, 2023
Autologous and allogeneic CAR T-cell therapies: spotlighting the "brain-to-vein" timeMatthew Lunning
Oncology (Williston Park, N.Y.)|June 20, 2022
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"Meghana Kesireddy, Matthew Lunning
Journal of Oncology Practice|June 12, 2019
Hepatosplenic γ-δ T-Cell Lymphoma: Who Is on Your Speed Dial?Mridula Krishnan, Matthew Lunning
Cancer Journal (Sudbury, Mass.)|May 21, 2026
Hodgkin Lymphoma: Introduction and HistoryJames Armitage, Matthew Lunning
The New England Journal of Medicine|September 17, 2025
Tumor Lysis SyndromeR Gregory Bociek, Matthew Lunning
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|October 16, 2007
The curability of follicular lymphomaMatthew Lunning, James O Armitage
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Addressing the Challenges of Aggressive LymphomasKatherine L Byar, Matthew Lunning
Leukemia & Lymphoma|June 17, 2024
Experience of using venetoclax in relapsed T- cell lymphomaJasmine Zain, Matthew Lunning, Steven Rosen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the ArtJeremy S Abramson, Matthew Lunning, M Lia Palomba
Current Hematologic Malignancy Reports|May 4, 2019
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLLAdam S Kittai, Matthew Lunning, Alexey V Danilov
Pageof 6